CD8A and neoplasm: STX-0119, the STAT3 inhibitor, demonstrates anti-tumor activity occurring through promoting TILs accumulation predominantly in the clonal expansion of CD8-postitive T cells and macrophages at TMZ-resistant U87 glioma tumor-site and humanized MHC-double knockout mouse (dKO-NOG) system, which has the potential to be a critical tool for assessing the impact of STAT3 inhibitors on human tumors (Akiyama et al., 2017).